Antiretroviral activity of protease inhibitors against Toxoplasma gondii;Terapia antiretroviral de inibidores da protease contra Toxoplasma gondii

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 55, Issue 1, 2013, Pages 65-67

  Monzote, Lianet ^a   Rodríguez, Marta ^a   Alfonso, Yenisey ^a   Cox, Raymundo ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Antiretroviral protease inhibitors; Toxoplasma gondii; Toxoplasmic encephalitis

Indexed keywords

ATAZANAVIR; FOSAMPRENAVIR; INDINAVIR; NELFINAVIR; PYRIMETHAMINE; RITONAVIR; SAQUINAVIR; SULFADIAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; FEMALE; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; FEMALE; HIV PROTEASE INHIBITORS; LETHAL DOSE 50; MICE; PARASITIC SENSITIVITY TESTS; TOXOPLASMA;

EID: 84872821556     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652013000100012     Document Type: Article

References (15)

1. Andrews KT, Fairlie DP, Madala PK, Ray J, Wyatt DM, Hilton PM, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother. 2006;50:639-48.
2. Bodley AL, McGarry MW, Shapiro TA. Drug cytotoxicity assay for African Trypanosomes and Leishmania species. J Infect Dis. 1995;172:1157-9.
3. Choi KM, Gang J, Yun J. Anti-Toxoplasma gondii RH strain activity of herbal extracts used in traditional medicine. Int J Antimicrob Agents. 2008;32:360-2.
4. de Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33:307-20.
5. Derouin F. Anti-toxoplasmosis drugs. Curr Opin Investing Drugs. 2001:2:1368-74.
6. Derouin F, Santillana-Hayat M. Anti-Toxoplasma activities drugs and interactions with Pyrimethamine and Sulfadiazine in vitro. Antimicrob Agents Chemother. 2009;44:2575-7.
7. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002;8:634-40.
8. McLeod R, Bensch KG, Smith SM, Remington JS. Effects of human peripheral blood monocytes, monocyte-derived macrophages and spleen mononuclear phagocytes on Toxoplasma gondii. Cell Immunol. 1980;54:330-50.
9. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363:1965-76.
10. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of Human Immunodeficiency Virus Type 1. Antimicrob Agents Chemother. 2005;49:2983-5.
11. Pozio E, Morales MA. The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol. 2005;21:58-63.
12. Santos LO, Marinho FA, Altoé EF, Vitório BS, Alves CR, Britto C, et al. HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. Plos One. 2009;4:e4918.
13. Savoia D, Allice T, Tovo PA. Antileishmanial activity of HIV protease inhibitors. Int J Antimicrob Agents. 2005;26:92-4.
14. Shea M, Jakle U, Liu Q, Berry C, Joiner KA, Soldati-Favre D. A family of aspartic proteases and a novel, dynamic and cell-cycle-dependent protease localization in the secretory pathway of Toxoplasma gondii. Traffic. 2007;8:1018-34.
15. Sladowski D, Steer SJ, Clothier RH, Balls M. An improved MTT assay. J Immunol Methods. 1993;157:203-7.